Bing

SEARCH HISTORY

OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED) 70% HIGHER; Oncomed and Celgene Corporation (Nasdaq: CELG) announced an agreement to jointly develop and commercialize up to six anti-cancer stem cell (CSC) product candidates from OncoMed's …
StreetInsider · 12/3/2013
ADVISORY, Feb 07, 2014 (GLOBE NEWSWIRE via COMTEX) -- What: OncoMed Pharmaceuticals, Inc. [OMED], a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, will visit the NASDAQ …
Market Watch · 2/7/2014
OncoMed Pharmaceuticals (OMED) has multiple early-stage cancer antibodies in its pipeline that are wholly owned or partnered with GlaxoSmithKline plc (GSK) and Bayer AG (FRA:BAYN) that could drive the stock to the upside by over 50%, says Ted …
The Wall Street Transcript · 9/24/2013
Biotech blue-chip stock ... most important collaborations for Celgene and its shareholders. You may not be able to follow all of its partnered programs, but you should certainly be keeping a close eye on these three. 1. OncoMed Pharmaceuticals (NASDAQ ...
Investopedia · 5/27/2015
OncoMed Pharmaceuticals (NASDAQ: OMED ) is soaring higher after announcing a development partnership with Celgene (NASDAQ ... maybe this will become the new standard in biotechnology. A top stock for the year ahead The market stormed out to …
The Motley Fool · 12/4/2013
The fund started new positions in a total of 17 stocks and didn’t sell out or increase holding or cut stake in any stock during the quarter ... positive bet in Oncomed Pharmaceuticals Inc (NASDAQ:OMED) during 1Q. The fund acquired nearly 1.7 million ...
investcorrectly.com · 5/18/2015
New York, NY - (ACCESSWIRE) - 12/03/2013 - Equity Profile Report initiates its NASDAQ Active Stock Weekly Watch List adding Unilife Corporation (NASDAQ:UNIS - News), OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED - News), Medallion Financial …
Finance Yahoo · 12/3/2013
NRG Yield (NYLD): Deutsche Bank has a Hold on the stock. OncoMed Pharmaceuticals (OMED): OMED is assigned an Overweight at Piper Jaffray. PMFG Inc (PMFG): Needham has a Hold on the diversified machinery name, as solid demand prospects …
Minyanville · ByJustin Sharon · 8/12/2013
OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) just went from being an obscure biotech to one ... For $155 million it secured rights to a drug pipeline. It also gets stock for $22 million or so that almost doubled in value. Celgene is worth some $66 billion ...
24/7 Wall ST · 12/3/2013
The stock market can’t seem to get enough of biotech IPOs these days, and OncoMed Pharmaceuticals is the latest company to cash in. Redwood City, CA-based OncoMed Pharmaceuticals (NASDAQ: OMED) sold 4.8 million shares to IPO investors …
Xconomy · ByLuke Timmerman · 7/18/2013